Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study

GW Albers, VE Bates, WM Clark, R Bell, P Verro… - Jama, 2000 - jamanetwork.com
ContextTissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke
approved by the Food and Drug Administration.ObjectiveTo assess the safety profile and to …

Predictors of fatal brain edema in massive hemispheric ischemic stroke

…, J Berrouschot, E Schmutzhard, L Harms, P Verro… - Stroke, 2001 - Am Heart Assoc
Background and Purpose— Early identification of stroke patients at risk for fatal brain edema
may be useful in selecting patients for aggressive interventions. Prior studies suggested …

Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study

…, EC Jauch, DJ Chang, P Verro… - Journal of Cerebral …, 2006 - journals.sagepub.com
Ischemic brain and peripheral white blood cells release cytokines, chemokines and other
molecules that activate the peripheral white blood cells after stroke. To assess gene …

Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis

P Verro, PB Gorelick, D Nguyen - Stroke, 2008 - Am Heart Assoc
Background and Purpose— This meta-analysis systematically reviewed randomized controlled
trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and …

Hemicraniectomy and durotomy upon deterioration from infarction-related swelling trial: randomized pilot clinical trial

…, D Wang, S Cruz-Flores, D Brock, A Demchuk, P Verro… - Stroke, 2014 - Am Heart Assoc
Background and Purpose— Hemicraniectomy and Durotomy Upon Deterioration From
Infarction-Related Swelling Trial (HeADDFIRST) was a randomized pilot study to obtain …

Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience

…, MJ Gorman, VE Bates, SE Kasner, P Scott, P Verro… - Stroke, 2000 - Am Heart Assoc
Background and Purpose—Intravenous tissue plasminogen activator (tPA) administered within
3 hours of symptom onset is the first available effective therapy for acute ischemic stroke (…

Signatures of cardioembolic and large‐vessel ischemic stroke

…, Y Tian, D Liu, RJ Turner, M Mesias, P Verro… - Annals of …, 2010 - Wiley Online Library
Objective: The cause of stroke remains unknown or cryptogenic in many patients. We
sought to determine whether gene expression signatures in blood can distinguish between …

Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location

…, BP Ander, X Zhan, D Liu, SM Sison, P Verro… - Stroke, 2012 - Am Heart Assoc
Background and Purpose— The cause of ischemic stroke remains unclear, or cryptogenic,
in as many as 35% of patients with stroke. Not knowing the cause of stroke restricts optimal …

CT angiography in acute ischemic stroke: preliminary results

P Verro, LN Tanenbaum, NM Borden, S Sen, N Eshkar - Stroke, 2002 - Am Heart Assoc
Background and Purpose— We sought to evaluate the ability of CT angiography (CTA) to
determine vessel occlusion before acute stroke treatment and to predict its impact on patient …

Cerebrovascular ischemic events with high positive anticardiolipin antibodies

P Verro, SR Levine, GE Tietjen - Stroke, 1998 - Am Heart Assoc
Background and Purpose—The aim of our study was to characterize the patient profile and
prognostic value associated with high positive IgG (>100 GPL) anticardiolipin antibodies (aCL…